Graph AI in talks to raise $14 million in funding

AI startup Graph AI, which focuses on the pharmaceutical sector, is reportedly in talks to raise $14 million (approximately ₹133 crore) in a Series A funding round, according to sources. The funding round is expected to be led by US-based Insight Partners and may include participation from existing investors such as Bessemer Venture Partners. However, the discussions are not finalized, and the funding amount could be subject to change. Graph AI offers its AI-native platform, 'Graph Safety,' designed to automate adverse drug event monitoring, regulatory submissions, and safety intelligence aggregation for pharmaceutical and biotech industries. The platform aims to unify data sources, case processing, aggregate reporting, signal detection, and risk management into a connected ecosystem. The company previously raised $3 million in seed funding eight months ago, led by Bessemer. The adoption of AI in drug discovery and safety is growing, with investors actively backing AI-native startups in the sector. Overall funding for Indian AI startups surged over fourfold year-on-year in the first six months of 2026, reaching $676 million.